Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 3, 2006, Pages 1098-1106

  Katchman, Alexander N ^a   Koerner, John ^b   Tosaka, Toshimasa ^a   Woosley, Raymond L ^c   Ebert, Steven N ^d  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c C Path Institute   (United States)

^d UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CHLORPHENIRAMINE; CIMETIDINE; CISAPRIDE; HALOPERIDOL; LIDOFLAZINE; LORATADINE; MEPYRAMINE; MEVINOLIN; PENTAMIDINE; POTASSIUM CHANNEL HERG; PRENYLAMINE; PROPAFENONE; SERTINDOLE; TERFENADINE; THIORIDAZINE;

ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; EMBRYO; EMBRYO CELL; EVALUATION; GENETIC TRANSFECTION; HEART PERFUSION; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN CELL; IC 50; KIDNEY CELL; NONHUMAN; PATIENT; PRIORITY JOURNAL; PROVOCATION TEST; QT INTERVAL; QT PROLONGATION; RABBIT; TORSADE DES POINTES;

ANIMALS; ARSENICALS; CELLS, CULTURED; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; HALOPERIDOL; HUMANS; LORATADINE; LOVASTATIN; METHADONE; OXIDES; PENTAMIDINE; POTASSIUM CHANNEL BLOCKERS; RABBITS; TERFENADINE; TORSADES DE POINTES;

EID: 33644782827     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.093393     Document Type: Article

References (39)

1. Asano Y, Davidenko JM, Baxter WT, Gray RA, and Jalife J (1997) Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart. J Am Coll Cardiol 29:831-842.
2. Barbey JT and Soignet S (2001) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 135:842-843.
3. Bibler MR, Chou TC, Toltzis RJ, and Wade PA (1988) Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity. Chest 94:1303-1306.
4. Bran S, Murray WA, Hirsch IB, and Palmer JP (1995) Long QT syndrome during high-dose cisapride. Arch Intern Med 155:765-768.
5. Brown AM (2004) Drugs, hERG and sudden death. Cell Calcium 35:543-547.
6. Chiang CE, Luk HN, Wang TM, and Ding PY (2002) Prolongation of cardiac repolarization by arsenic trioxide. Blood 100:2249-2252.
7. Connolly SJ, Kates RE, Lebsack CS, Echt DS, Mason JW, and Winkle RA (1983) Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol 52:1208-1213.
8. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW, Chen X, and Zhou J (2005) Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 145:15-23.
9. (+) channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 292:261-264.
10. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, and Keating MT (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795-803.
11. Davie C, Pierre-Valentin J, Pollard C, Standen N, Mitcheson J, Alexander P, and Thong B (2004) Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel. J Cardiovasc Electrophysiol 15:1302-1309.
12. Drici MD, Ebert SN, Wang WX, Rodriguez I, Liu XK, Whitfield BH, and Woosley RL (1999) Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol 34:82-88.
13. Drolet B, Simard C, and Roden DM (2004) Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 109:26-29.
14. Drolet B, Vincent F, Rail J, Chahine M, Deschenes D, Nadeau S, Khalifa M, Hamelin BA, and Turgeon J (1999) Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 288:1261-1268.
15. + channels. J Cardiovasc Pharmacol 30:42-54.
16. Eckhardt LL, Rajamani S, and January CT (2005) Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome. Br J Pharmacol 145:3-4.
17. Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne PE Jr, and Wortham DC (1994) Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 105:389-395.
18. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, and Cantilena LR (2004) Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15:475-495.
19. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, Wible BA, and Brown AM (2004) Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66:33-44.
20. Guijarro MA, Raya PA, Martin Navajas JA, Gonzalez SP, Marti Garcia JL, Morata GF, and Rosaio DE (1976) [Long QT, syncope caused by atypical ventricular fibrillation and chronic ingestion of prenylamine (review of the literature and report of a case]. Rev Clin Esp 142:163-170.
21. Hanley SP and Hampton JR (1983) Ventricular arrhythmias associated with lidoflazine: side-effects observed in a randomized trial. Eur Heart J 4:889-893.
22. (+) currents. J Pharmacol Exp Ther 303:688-694.
23. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, et al. (2003) QTc interval prolongation associated with intravenous methadone. Pain 105:499-506.
24. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, et al. (2005) Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312:316-323.
25. Lehmann MH, Timothy KW, Frankovich D, Fromm BS, Keating M, Locati EH, Taggart RT, Towbin JA, Moss AJ, Schwartz PJ, et al. (1997) Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol 29:93-99.
26. Liu X, Katchman A, Whitfield B, Wan G, Janowski E, Woosley R, and Ebert S (2003) In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. Cardiovasc Res 57:28-36.
27. Liu XK, Wang W, Ebert SN, Franz MR, Katchman A, and Woosley RL (1999) Female gender is a risk factor for torsades de pointes in an in vitro animal model. J Cardiovasc Pharmacol 34:287-294.
28. Makkar RR, Fromm BS, Steinman RT, Meissner MD, and Lehmann MH (1993) Female gender as a risk factor for Torsades de Pointes associated with cardiovascular drugs. J Am Med Assoc 270:2590-2597.
29. Nattel S (1999) The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 10:272-282.
30. Oakley D, Jennings K, Puritz R, Krikler D, and Chamberlain D (1980) The effect of prenylamine on the QT interval of the resting electrocardiogram in patients with angina pectoris. Postgrad Med J 56:753-756.
31. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, et al. (2000) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133:881-885.
32. Shah RR and Hondeghem LM (2005) Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2:758-772.
33. Stein KM, Fenton C, Lehany AM, Okin PM, and Kligfield P (1991) Incidence of QT interval prolongation during pentamidine therapy of Pneumocystis carinii pneumonia. Am J Cardiol 68:1091-1094.
34. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, Wiernik PH, and Chiaramida S (2001) Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97:1514-1516.
35. Vohringer HF and Arasteh K (1993) Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. Clin Pharmacokinet 24:388-412.
36. Wharton JM, Demopulos PA, and Goldschlager N (1987) Torsade de pointes during administration of pentamidine isethionate. Am J Med 83:571-576.
37. Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, and Brown AM (2005) HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 52:136-145.
38. Woosley RL (1996) Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 36:233-252.
39. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, and January CT (1998) Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 74:230-241.